Semih Can Akıncılar

Semih Can Akıncılar

Auto-generated profile, based on publicly available information

Semih Can Akıncılar

A*STAR Division of Cancer Genetics, Institute of Molecular and Cell Biology (IMCB), Singapore, Singapore

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2023 in Nature
Verified
Journal Article
Open access
PDF file
JNJoe Nassour
Joe Nassour
LALucia Gutierrez Aguiar
Lucia Gutierrez Aguiar
ACAdriana Correia
Adriana Correia
TSTobias T. Schmidt
Tobias T. Schmidt
LMLaura Mainz
Laura Mainz
JKJan Karlseder
Jan Karlseder
Cancers arise through the accumulation of genetic and epigenetic alterations that enable cells to evade telomere-based proliferative barriers and achieve immortality. One such barrier is replicative crisis—an autophagy-dependent program that eliminates checkpoint-deficient cells with unstable telomeres and other cancer-relevant chromosomal aberrations1,2. However, little is known about the molecular events that regulate the onset of this important tumour-suppressive barrier. Here we identified the innate immune sensor Z-DNA binding protein 1 (ZBP1) as a regulator of the crisis program. A crisis-associated isoform of ZBP1 is induced by the cGAS–STING DNA-sensing pathway, but reaches full activation only when associated with telomeric-repeat-containing RNA (TERRA) transcripts that are synthesized from dysfunctional telomeres. TERRA-bound ZBP1 oligomerizes into filaments on the outer mitochondrial membrane of a subset of mitochondria, where it activates the innate immune adapter protein mitochondrial antiviral-signalling protein (MAVS). We propose that these oligomerization properties of ZBP1 serve as a signal amplification mechanism, where few TERRA–ZBP1 interactions are sufficient to launch a detrimental MAVS-dependent interferon response. Our study reveals a mechanism for telomere-mediated tumour suppression, whereby dysfunctional telomeres activate innate immune responses through mitochondrial TERRA–ZBP1 complexes to eliminate cells destined for neoplastic transformation.

25 November 2020 in Gut
Verified
Journal Article
Open access
PDF file
SASemih Can Akıncılar
Semih Can Akıncılar
LWLele Wu
Lele Wu
QNQin Feng Ng
Qin Feng Ng
JCJoelle Yi Heng Chua
Joelle Yi Heng Chua
BUBilal Unal
Bilal Unal
Vinay TergaonkarVinay Tergaonkar
Vinay Tergaonkar
Objective: NFκB is the key modulator in inflammatory disorders. However, the key regulators that activate, fine-tune or shut off NFκB activity in inflammatory conditions are poorly understood. In this study, we aim to investigate the roles that NFκB-specific long non-coding RNAs (lncRNAs) play in regulating inflammatory networks. Design: Using the first genetic-screen to identify NFκB-specific lncRNAs, we performed RNA-seq from the p65-/- and Ikkβ -/- mouse embryonic fibroblasts and report the identification of an evolutionary conserved lncRNA designated mNAIL (mice) or hNAIL (human). hNAIL is upregulated in human inflammatory disorders, including UC. We generated mNAILΔNFκB mice, wherein deletion of two NFκB sites in the proximal promoter of mNAIL abolishes its induction, to study its function in colitis. Results: NAIL regulates inflammation via sequestering and inactivating Wip1, a known negative regulator of proinflammatory p38 kinase and NFκB subunit p65. Wip1 inactivation leads to coordinated activation of p38 and covalent modifications of NFκB, essential for its genome-wide occupancy on specific targets. NAIL enables an orchestrated response for p38 and NFκB coactivation that leads to differentiation of precursor cells into immature myeloid cells in bone marrow, recruitment of macrophages to inflamed area and expression of inflammatory genes in colitis. Conclusion: NAIL directly regulates initiation and progression of colitis and its expression is highly correlated with NFκB activity which makes it a perfect candidate to serve as a biomarker and a therapeutic target for IBD and other inflammation-associated diseases.

14 June 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SASemih Can Akıncılar
Semih Can Akıncılar
JCJoelle Yi Heng Chua
Joelle Yi Heng Chua
QNQin Feng Ng
Qin Feng Ng
CCClaire Hian Tzer Chan
Claire Hian Tzer Chan
ZEZahra Eslami-S
Zahra Eslami-S
Vinay TergaonkarVinay Tergaonkar
Vinay Tergaonkar
Transcriptional reactivation of hTERT is the limiting step in tumorigenesis. While mutations in hTERT promoter present in 19% of cancers are recognized as key drivers of hTERT reactivation, mechanisms by which wildtype hTERT (WT-hTERT) promoter is reactivated, in majority of human cancers, remain unknown. Using primary colorectal cancers (CRC) we identified Tert INTeracting region 2 (T-INT2), the critical chromatin region essential for reactivating WT-hTERT promoter in CRCs. Elevated β-catenin and JunD level in CRC facilitates chromatin interaction between hTERT promoter and T-INT2 that is necessary to turn on hTERTexpression. Pharmacological screens uncovered salinomycin, which inhibits JunD mediated hTERT-T-INT2 interaction that is required for the formation of a stable transcription complex on the hTERT promoter. Our results showed for the first time how known CRC alterations, such as APC, lead to WT-hTERT promoter reactivation during stepwise-tumorigenesis and provide a new perspective for developing cancer-specific drugs. Healthy and cancer cells harbor the same DNA sequence, but reactivation of the Human Telomerase Reverse Transcriptase (hTERT) gene is observed only in cancer cells. How does that happen was not known for over three decades of research? This study identifies a specific DNA structure that forms only in cancer cells and brings the necessary molecular machinery into the correct position to activate the hTERT gene. The detailed mechanism of hTERT activation provided in this study will be instrumental in designing cancer cell-specific hTERT inhibitors, especially since all the other ways of inhibiting telomerase failed in the clinic.

13 January 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RSRaghuvaran Shanmugam
Raghuvaran Shanmugam
MOMert Burak Ozturk
Mert Burak Ozturk
JLJoo-Leng Low
Joo-Leng Low
SASemih Can Akincilar
Semih Can Akincilar
JCJoelle Yi Heng Chua
Joelle Yi Heng Chua
Vinay TergaonkarVinay Tergaonkar
Vinay Tergaonkar
Significance: Mutations in hTERT promoter are seen in over 19% of human cancers, irrespective of the cancer type. Understanding the molecular players that regulate Mut- hTERT promoters may help the design of effective targeting strategies to inhibit telomerase reactivation specifically in cancer cells. Our work uses genome-wide functional screens to identify 30 specific regulators of Mut- hTERT promoters. These candidates identified from the screening serve as an excellent resource to understand how telomerase is reactivated and as targets for making inhibitors to telomerase, a key driver of cancer.

3 April 2023
Verified
Other
Open access
SASemih Can Akıncılar
Semih Can Akıncılar
Ekta KhattarEkta Khattar
Ekta Khattar
PBPriscilla Li Shan Boon
Priscilla Li Shan Boon
BUBilal Unal
Bilal Unal
MFMelissa Jane Fullwood
Melissa Jane Fullwood
Vinay TergaonkarVinay Tergaonkar
Vinay Tergaonkar

3 April 2023
Verified
Other
Open access
SASemih Can Akıncılar
Semih Can Akıncılar
Ekta KhattarEkta Khattar
Ekta Khattar
PBPriscilla Li Shan Boon
Priscilla Li Shan Boon
BUBilal Unal
Bilal Unal
MFMelissa Jane Fullwood
Melissa Jane Fullwood
Vinay TergaonkarVinay Tergaonkar
Vinay Tergaonkar
Supplementary Table 1. Differential gene expression data list of BLM6 and BLM14 cells (-146C>T vs. -146C) for the genes that were predicted to be off-targets of the guide RNA that has been used for the CRISPR/Cas9 genome engineering. Supplementary Table 2. Table showing list of interacting regions obtained from 4C analysis. 4C was performed in BLM6 and BLM14 cells. Differential interactions were obtained from 4C analysis. List shows the genomic coordinates (column 1-3) and their Refseq identities (column 4) of regions interacting with mutant Tert promoter. Column 5 shows whether the regions were tested by 3C-qPCR assay. Y = Yes, N=No. Column 6 shows whether the region was removed by CRISPR/Cas9 editing in the later part of the study. * mark is named as T-INT1 region. Supplementary Table 3. Primer sequences for ChIP-qPCR, 4C and 3C and RT-qPCR experiments.